Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005–20.

Article  PubMed  CAS  Google Scholar 

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.

Article  PubMed  CAS  Google Scholar 

Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, Gallardo C, et al. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3‑Year Follow-Up of the Phase III CheckMate 649 Trial. J Clin Oncol. 2024;42(17):2012–20.

Article  PubMed  CAS  Google Scholar 

Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402(10418):2197–208.

Article  PubMed  CAS  Google Scholar 

Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ. 2024;385:e78876.

Article  PubMed  CAS  Google Scholar 

Rha SY, Oh DY, Yanez P, Bai Y, Ryu MH, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181–95.

Article  PubMed  CAS  Google Scholar 

Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133–41.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655–68.

Article  PubMed  CAS  Google Scholar 

Zihni C, Mills C, Matter K, Balda MS. Tight junctions: from simple barriers to multifunctional molecular gates. Nat Rev Mol Cell Biol. 2016;17(9):564–80.

Article  PubMed  CAS  Google Scholar 

Schneeberger EE, Lynch RD. Structure, function, and regulation of cellular tight junctions. Am J Physiol. 1992;262(6 Pt 1:L647–61.

Google Scholar 

Furuse M, Fujita K, Hiiragi T, Fujimoto K, Tsukita S. Claudin‑1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol. 1998;141(7):1539–50.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14(23):7624–34.

Article  PubMed  CAS  Google Scholar 

Hedrick L, Cho KR, Vogelstein B. Cell adhesion molecules as tumour suppressors. Trends Cell Biol. 1993;3(2):36–9.

Article  PubMed  CAS  Google Scholar 

Morin PJ. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res. 2005;65(21):9603–6.

Article  PubMed  CAS  Google Scholar 

Nakayama I, Qi C, Chen Y, Nakamura Y, Shen L, Shitara K. Claudin 18.2 as a novel therapeutic target. Nat Rev Clin Oncol. 2024;21(5):354–69.

Article  PubMed  Google Scholar 

Shitara K, Xu RH, Ajani JA, Moran D, Guerrero A, Li R, et al. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Gastric Cancer. 2024;27(5):1058–68.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Pellino A, Brignola S, Riello E, Niero M, Murgioni S, Guido M, et al. Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas. J Pers Med. 2021;11(11).

Arnold A, Daum S, von Winterfeld M, Berg E, Hummel M, Rau B, et al. Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas. Clin Transl Oncol. 2020;22(12):2357–63.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kubota Y, Kawazoe A, Mishima S, Nakamura Y, Kotani D, Kuboki Y, et al. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. Esmo Open. 2023;8(1):100762.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Son SM, Woo CG, Lee OJ, Lee SK, Cho M, Lee YP, et al. Discordance in Claudin 18.2 Expression Between Primary and Metastatic Lesions in Patients With Gastric Cancer. J Gastric Cancer. 2025;25(2):303–17.

Article  PubMed  Google Scholar 

Tureci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, et al. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol. 2019;30(9):1487–95.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sahin U, Tureci O, Manikhas G, Lordick F, Rusyn A, Vynnychenko I, et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021;32(5):609–19.

Article  PubMed  CAS  Google Scholar 

Shitara K, Shah MA, Lordick F, Van Cutsem E, Ilson DH, Klempner SJ, et al. Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma. N Engl J Med. 2024;391(12):1159–62.

Article  PubMed  PubMed Central  Google Scholar 

Lordick F, Van Cutsem E, Shitara K, Xu RH, Ajani JA, Shah MA, et al. Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials. Esmo Open. 2024;9(8):103663.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lordick F, Al-Batran S, Arnold D, Borner M, Bruns C, Eisterer W, et al. Magenkarzinomleitlinien www.onkopedia.com2023.

Korpan M, Puhr HC, Berger JM, Friedrich A, Prager GW, Preusser M, et al. Current Landscape of Molecular Biomarkers in Gastroesophageal Tumors and Potential Strategies for Co-Expression Patterns. Cancers (basel). 2025;17(3).

Jia K, Chen Y, Sun Y, Hu Y, Jiao L, Ma J, et al. Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer. BMC Med. 2022;20(1):223.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Klempner SJ, Lee KW, Shitara K, Metges JP, Lonardi S, Ilson DH, et al. ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma. Clin Cancer Res. 2023;29(19):3882–91.

Article  PubMed  PubMed Central  CAS  Google Scholar 

FDA. 2024. https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-26-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-09262024#event-materials

Formica V, Morelli C, Fornaro L, Riondino S, Rofei M, Fontana E, et al. PD-L1 thresholds predict efficacy of immune checkpoint inhibition in first-line treatment of advanced gastroesophageal adenocarcinoma. A systematic review and meta-analysis of seven phase III randomized trials. Esmo Open. 2024;9(11):103967.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Leone AG, Mai AS, Fong KY, Yap DWT, Kato K, Smyth E, et al. Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups. Esmo Open. 2024;9(11):103962.

Article  PubMed  PubMed Central  CAS